Home
    Disclaimer
    Oxiracetam molecular structure

    Oxiracetam Stats & Data

    Ct-848 Isf 2522 Neuromet Neuractiv Cgp-21690e hydroxypiracetam
    NPS DataHub
    MW158.16
    FormulaC6H10N2O3
    CAS62613-82-5
    IUPAC2-(4-Hydroxy-2-oxopyrrolidin-1-yl)acetamide
    SMILESNC(=O)CN1CC(O)CC1=O
    InChIKeyIHLAQQPQKRMGSS-UHFFFAOYSA-N
    Psychoactive Class Stimulant
    Half-Life ~8 hours reported anecdotally; limited accessible clinical PK data in open sources.

    Receptor Profile

    Receptor Actions

    Modulators
    AMPA receptor positive allosteric modulator
    Other
    Acetylcholine release enhancer

    Effect Profile

    Curated + 7 Reports
    Stimulant 7.0

    Strong focus and stimulation with low euphoria and anxiety/jitters

    Stimulation / Energy×3
    8
    Euphoria / Mood Lift×2
    2
    Focus / Productivity×2
    10
    Anxiety / Jitters×1
    2

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    ~8 hours reported anecdotally; limited accessible clinical PK data in open sources.
    Addiction Potential
    Low; no evidence of classical dependence patterns in clinical or user communities, but habituation to daily use is reported by some.

    Tolerance Decay

    Full tolerance 14d Half tolerance 3d Baseline ~30d

    Tolerance appears to build gradually with frequent daily use and decays over weeks after cessation, based on user patterns with racetams generally; consider cycling (e.g., 5 days on, 2 off, or 2–4 weeks on, 1–2 weeks off) to maintain effect and reduce escalation. Data are anecdotal.

    Cross-Tolerances

    Other racetams (e.g., piracetam, aniracetam)
    40% ●○○

    Experience Report Analysis

    Erowid
    7 Reports
    2007–2014 Date Range
    5 With Age Data
    4 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 7 experience reports (7 Erowid)

    7 Reports
    4 Effects Detected
    3 Positive
    0 Adverse
    1 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 3

    Euphoria 42.9% 70%
    Stimulation 42.9% 70%
    Focus Enhancement 42.9% 70%

    Adverse Effects 0

    Real-World Dose Distribution

    62K Doses

    From 14 individual dose entries

    Oral (n=14)

    Median: 1000.0mg 25th: 1000.0mg 75th: 1150.0mg 90th: 1500.0mg
    mg/kg median: 12.129 mg/kg 75th: 13.483

    Form / Preparation

    Most common forms and preparations reported

    Harm Reduction

    drugs.wiki

    • Product misrepresentation is a known risk with research chemicals; verify identity and weigh doses precisely with a milligram scale. TripSit warns RCs are often mislabelled and that initial doses should be conservative until identity and potency are established.

    • Start low and divide doses to limit jitteriness and GI upset; several community threads describe stimulant-like effects and stomach issues at higher single doses. Label dosing devices (scoops) are unreliable; a scale is recommended.

    • Avoid dosing late in the day; users commonly report insomnia or sleep disruption when taken in the afternoon or evening.

    • Combining with choline donors can reduce racetam‑associated headaches in some but may also increase stimulation, anxiety, or headaches if choline load is excessive; adjust choline slowly if used.

    • Concurrent use with CNS depressants (opioids, benzodiazepines, sedatives) can increase CNS depression risk per DrugBank’s interaction listings; avoid or use only under medical oversight.

    • Limit stacking with other stimulants (e.g., high caffeine, modafinil) to reduce risk of tachycardia, anxiety, and insomnia; space compounds and test combinations cautiously. General stimulant HR principles apply.

    • Some reports suggest racetams can potentiate MDMA’s acute effects and alter the comedown; given uncertainty and interindividual variability, avoid this combination or proceed only with strong experience and conservative dosing.

    • Pharmacokinetic human data are limited in open sources; treat use in renal impairment, pregnancy, or breastfeeding as higher risk and consider avoidance or medical guidance due to uncertain elimination and lack of safety data. DrugBank lists Oxiracetam as investigational with sparse PK fields.

    • Take with food and adequate hydration to mitigate nausea or GI discomfort reported anecdotally.

    • Do not rely on subjective clarity to judge fitness to drive or operate machinery; stimulant-like effects can mask impairment or cause over‑arousal. Follow general driving HR advice and avoid until individual response is known.

    ← Back to Oxiracetam